- [Resource Hub](/) - [Resource](/?resource-type=poster#library) - Novel method for the detection and evaluation of disease biomarkers on white blood cells from liquid biopsies # Novel method for the detection and evaluation of disease biomarkers on white blood cells from liquid biopsies The RareCyte platform was built to find rare circulating tumor cells; this AACR 2023 poster from RareCyte and Eli Lilly reuses the same stained slide to quantify monocyte and granulocyte subpopulations, to detect spiked tumor cells alongside them, and to measure an undisclosed drug-target biomarker across all three populations. Presented by RareCyte. Read or download to see: - A platform built to find rare tumor cells was turned on the abundant cells around them. AccuCyte, an unbiased density-based method, moves nucleated cells from whole blood onto a slide stained for CD14, CD66b, CK/EpCAM, Sytox and the biomarker; new scanning and analysis algorithms then quantify monocyte and granulocyte subpopulations alongside rare tumor cells, from among the millions of cells each slide carries, with imaging on CyteFinder. - Monocyte and granulocyte percentages tracked the standard CBC from the same donors. Across three donors the assay read monocytes at 8.4%, 6.4% and 6.7% where CBC read 8.3%, 7.4% and 7.1%, and granulocytes at 63.5%, 72.0% and 51.3% where CBC read 65.6%, 73.3% and 57.7%. CBCs were measured from EDTA tubes and the assay from AccuCyte tubes; the widest gap is the granulocyte reading in the third donor, and the poster reports no correlation statistic. - An undisclosed drug-target biomarker read higher on monocytes than on granulocytes. Mean fluorescence intensity was aggregated from three replicate slides, with whiskers spanning the 5th to 95th percentile. The same ranking held in a second run of two replicate slides that added BT474 breast-cancer-derived cells spiked into whole blood, where the biomarker sat lowest on those tumor cells; the poster names neither the biomarker nor a statistical test for the difference. [Download poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) Your browser doesn’t support embedded PDFs. [Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) to view it. [Back to all resources](/#library) ## Related resources [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025 ### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) CyteFinder 2024 ### New Discoveries in HER2 Detection: A Novel Method of Multimodal Detection of HER2 from a Single Tube of Blood [Watch Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) CyteFinder 2024 ### Development and analytic validation of an ARv7 / PSMA dual biomarker circulating tumor cell assay [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) CyteFinder 2024 ### Development and validation of an assay for the characterization of SSTR2 expression on CTCs from liquid biopsies [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) CyteFinder The Journal of Liquid Biopsy 2023 ### Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) CyteFinder 2020 ### Validation of a dual-marker ARv7/SYP assay for CTC characterization [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) CyteFinder 2020 ### Analytic validation of an assay to detect androgen receptor splice variant ARv7 protein expression on circulating tumor cells from prostate cancer patients [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf) CyteFinder 2020 ### Investigation of custom biomarkers on circulating tumor cells from clinical samples using RarePlex Developer Kits [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf) [Video](https://www.youtube.com/watch?v=A0dhlNEaohs) CyteFinder 2020 ### RarePlex Assays: Design and Analytical Validation [Watch Video](https://www.youtube.com/watch?v=A0dhlNEaohs) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) CyteFinder 2020 ### Validation of an assay to detect programmed death-ligand 1 (PD-L1) expression on circulating tumor cells [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf) CyteFinder 2019 ### Custom biomarker investigation of circulating tumor cells using RarePlex® Developer Kits [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/886b7272733f331d2bd933c9cfa2bb97ce0e9542.pdf) CyteFinder 2018 ### Novel multi-parameter assays for investigational phenotyping of circulating tumor cells [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/886b7272733f331d2bd933c9cfa2bb97ce0e9542.pdf)